Zobrazeno 1 - 5
of 5
pro vyhledávání: '"624"'
Autor:
Feng Yang, Fanlin Meng, Jing Wang, Xiaowen Chen, Shuyuan Wang, Xuexin Yu, Dianming Liu, Wei Jiang, Enyu Dai
Publikováno v:
Scientific Reports
miRNAs are key post-transcriptional regulators of many essential biological processes and their dysregulation has been validated in almost all human cancers. Restoring aberrantly expressed miRNAs might be a novel therapeutics. Recently, many studies
Publikováno v:
Journal of Cellular Physiology. 221:109-119
MicroRNAs (miRNAs) are small non-coding RNAs that regulate diverse genetic expression networks through their control of mRNA stability or translation. Their role in aging mechanisms has been proposed in various model systems. In this report, the expr
Autor:
Consuelo Diaz, Gilberto Lopez-Rosas, Abelardo Meneses-García, Jesús Moreno, Ortega A, César López-Camarillo, Erika Ruiz Garcia, German Caderillo-Ruiz, Alicia Lopez-Yanez, Marytere Herrera, Horacio Astudillo, Laurence A. Marchat, Leonardo S. Lino-Silva, Silvio A. Ñamendys-Silva, Itzel Vela Sarmiento
Publikováno v:
Journal of Clinical Oncology. 34:624-624
624 Background: Neoadjuvant chemoradiotherapy (nCRT) follow by surgery, as treatment for locally advanced rectal carcinoma (LARC), has improve local disease control, increase of complete pathological response (cPR) and preserve anal sphincter. cPR is
Autor:
Andrea Bott, Benedikt Brors, Susanne N.E. Boehn, Prashant K. Srivastava, Priyanka Pandey, Herrmann Josef Groene, Norbert Gretz
Publikováno v:
BMC Genomics, Vol 9, Iss 1, p 624 (2008)
BMC Genomics
BMC Genomics
Background MicroRNAs (miRNAs) play key roles in mammalian gene expression and several cellular processes, including differentiation, development, apoptosis and cancer pathomechanisms. Recently the biological importance of primary cilia has been recog
Autor:
Izidore S. Lossos, Alvaro J. Alencar, Randy D. Gascoyne, Ranjana H. Advani, Robert Tibshirani, Ragini Shyam, Yaso Natkunam, Neha Talreja, Raquel Malumbres, Javier Briones
Publikováno v:
Blood. 114:624-624
Abstract 624 Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with a variable clinical outcome even in the current era of rituximab containing anthracycline-based chemotherapy (RCHOP). We have previously reported a 6 gene